New hope for tough lymphoma: three-drug combo enters early trials
NCT ID NCT07269639
First seen Jan 05, 2026 · Last updated May 16, 2026 · Updated 16 times
Summary
This early-phase trial tests a combination of three drugs (golcadomide, poseltinib, and rituximab) in 20 adults with relapsed or refractory large B-cell lymphoma. The goal is to see if the combination can shrink or eliminate tumors. Participants must have tried other treatments first. This is not a cure, but aims to control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LARGE B-CELL LYMPHOMA (LBCL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Seoul National University Hospital
Seoul, 03080, South Korea
Conditions
Explore the condition pages connected to this study.